Staging and clinical prognostic factors for small-cell lung cancer

Cancer Journal

Volumn 7, Issue 5, 2001, Pages 437-447

  Argiris, Athanassios ^a,b   Murren, John R ^a,c  

^a Robert H Lurie Comprehensive Cancer Center ^*

^b NORTHWESTERN UNIVERSITY   (United States)

^c YALE CANCER CENTER   (United States)

Author keywords

Prognostic factors; Small cell lung cancer; Staging

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; VINCRISTINE; LACTATE DEHYDROGENASE; TUMOR PROTEIN;

ADRENAL METASTASIS; AUTOPSY; BLOOD CELL COUNT; BONE MARROW BIOPSY; BONE MARROW METASTASIS; BONE METASTASIS; BONE SCINTISCANNING; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LIVER METASTASIS; LUNG SMALL CELL CANCER; LYMPHADENOPATHY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFORMANCE; PHYSICAL EXAMINATION; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; SURGICAL TECHNIQUE; THORAX RADIOGRAPHY; FEMALE; LUNG TUMOR; MALE; METASTASIS; METHODOLOGY; PATHOLOGY; SEX DIFFERENCE; SMALL CELL CARCINOMA; SURVIVAL;

CARCINOMA, SMALL CELL; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LUNG NEOPLASMS; MALE; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; SEX FACTORS; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0035461994     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Greenlee RT, Murray T, Bolden SV et al. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 1973;(part 3)4:31-42.
3. Lassen U, Osterlind K, Hansen M et al. Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years-an analysis of 1,714 consecutive patients. J Clin Oncol 1995;13:1215-1220.
4. Spiegelman D, Maurer LH, Ware JH et al. Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. J Clin Oncol 1989;7:344-354.
5. Albain KS, Crowley JJ, Livingston RB. Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. Chest 1991;99:1425-1432.
6. Pignon JP, Arriagada R, Ihde DC et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327: 1618-1624.
7. Perry MC, Eaton WL, Propert KJ et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987;316:912-918.
8. Bonner JA, Sloan JA, Shanahan TG et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 1999;17:2681-2691.
9. Turrisi AT 3rd, Kim K, Blum R et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-271.
10. Jeremic B, Shibamoto Y, Nikolic N et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol 1999;17:2092-2099.
11. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717.
12. Karrer K, Ulsperger E. Surgery for cure followed by chemotherapy in small cell carcinoma of the lung. For the ISC-Lung Cancer Study Group. Acta Oncol 1995;34:899-906.
13. Sagman U, Maki E, Evans WK et al. Small-cell carcinoma of the lung: derivation of a prognostic staging system. J Clin Oncol 1991;9:1639-1649.
14. Harper PG, Houang M, Spiro SG et al. Computerized axial tomography in the pretreatment assessment of small-cell carcinoma of the bronchus. Cancer 1981;47:1775-1780.
15. Norlund JD, Byhardt RW, Foley WD et al. Computed tomography in the staging of small cell lung cancer: implications for combined modality therapy. Int J Radiat Oncol Biol Phys 1985;11: 1081-1084.
16. Dearing MP, Steinberg SM, Phelps R et al. Outcome of patients with small-cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years. J Clin Oncol 1990;8:1042-1049.
17. Livingston RB, McCracken JD, Trauth CJ et al. Isolated pleural effusion in small cell lung carcinoma: favorable prognosis. A review of the Southwest Oncology Group experience. Chest 1982; 81:208-211.
18. Albain KS, Crowley JJ, LeBlanc M et al. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990; 8:1563-1574.
19. Chauvin F, Trillet V, Court-Fortune I et al. Pretreatment staging evaluation in small cell lung carcinoma: a new approach to medical decision making. Chest 1992;102:497-502.
20. Shepherd FA, Ginsberg RJ, Haddad R et al. Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. The University of Toronto Lung Oncology Group. J Clin Oncol 1993;11:1592-1597.
21. Stahel RA, Ginsberg R, Havemann K et al. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 1989;5:119-126.
22. Osterlind K, Hansen HH, Hansen HS et al. Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer: results of a controlled trial with 5 years follow-up. Br J Cancer 1986;54:7-17.
23. Work E, Nielsen OS, Bentzen SM et al. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group. J Clin Oncol 1997;15:3030-3037.
24. Murray N, Coy P, Pater JL et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993;11:336-344.
25. Bunn PA Jr, Lichter AS, Makuch RW et al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer: a prospective, randomized trial. Ann Intern Med 1987;106:655-662.
26. Urban T, Chastang C, Vaylet F et al. Prognostic significance of supraclavicular lymph nodes in small cell lung cancer: a study from four consecutive clinical trials, including 1,370 patients. "Petites Cellules" Group. Chest 1998;114:1538-1541.
27. Vincent MD, Ashley SE, Smith IE. Prognostic factors in small cell lung cancer: a simple prognostic index is better than conventional staging. Eur J Cancer Clin Oncol 1987;23:1589-1599.
28. Maestu I, Pastor M, Gomez-Codina J et al. Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients. Ann Oncol 1997;8:547-553.
29. Richardson GE, Venzon DJ, Edison M et al. Application of an algorithm for staging small-cell lung cancer can save one third of the initial evaluation costs. Arch Intern Med 1993;153:329-337.
30. Tritz DB, Doll DC, Ringenberg QS et al. Bone marrow involvement in small cell lung cancer: clinical significance and correlation with routine laboratory variables. Cancer 1989;63:763-766.
31. Sagman U, Feld R, Evans WK et al. The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer. J Clin Oncol 1991;9:954-961.
32. Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986;46: 4189-4194.
33. Byhardt RW, Hartz A, Libnoch JA et al. Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL). Int J Radiat Oncol Biol Phys 1986;12:771-777.
34. Stokkel MP, van Eck-Smit BL, Zwinderman AH et al. Pretreatment serum lactate dehydrogenase as additional staging parameter in patients with small-cell lung carcinoma. J Cancer Res Clin Oncol 1998;124:215-219.
35. Gronowitz JS, Bergstrom R, Nou E et al. Clinical and serologic markers of stage and prognosis in small cell lung cancer: a multivariate analysis. Cancer 1990;66:722-732.
36. Whitley NO, Fuks JZ, McCrea ES et al. Computed tomography of the chest in small cell lung cancer: potential new prognostic signs. AJR Am J Roentgenol 1984;142:885-892.
37. Vas W, Zylak CJ, Mather D, Figueredo A. The value of abdominal computed tomography in the pre-treatment assessment of small cell carcinoma of the lung. Radiology 1981;138:417-418.
38. Dunnick NR, Ihde DC, Johnston-Early A. Abdominal CT in the evaluation of small cell carcinoma of the lung. AJR Am J Roentgenol 1979;133:1085-1088.
39. Ihde DC, Dunnick NR, Johnston-Early A et al. Abdominal computed tomography in small cell lung cancer: assessment of extent of disease and response to therapy. Cancer 1982;49:1485-90.
40. Mirvis SE, Whitley NO, Aisner J et al. Abdominal CT in the staging of small-cell carcinoma of the lung: incidence of metastases and effect on prognosis. AJR Am J Roentgenol 1987;148:845-847.
41. Mulshine JL, Makuch RW, Johnston-Early A et al. Diagnosis and significance of liver metastases in small cell carcinoma of the lung. J Clin Oncol 1984;2:733-741.
42. Elliott JA, Osterlind K, Hirsch FR et al. Metastatic patterns in small-cell lung cancer: correlation of autopsy findings with clinical parameters in 537 patients. J Clin Oncol 1987;5:246-254.
43. Takita H, Brugarolas A, Marabella P et al. Small cell carcinoma of the lung: clinicopathological studies. J Thorac Cardiovasc Surg 1973;66:472-477.
44. Korobkin M, Dunnick RN. Characterization of adrenal masses. AJR 1995;164:643-644.
45. Porte HL, Ernst OJ, Delebecq T et al. Is computed tomography guided biopsy still necessary for the diagnosis of adrenal masses in patients with resectable non-small-cell lung cancer? Eur J Cardiothorac Surg 1999;15:597-601.
46. Oliver TW Jr, Bernardino ME, Miller JI et al. Isolated adrenal masses in nonsmall-cell bronchogenic carcinoma. Radiology 1984;153:217-218.
47. Pagani JJ. Normal adrenal glands in small cell lung carcinoma: CT-guided biopsy. AJR Am J Roentgenol 1983;140:949-951.
48. Schwanz LH, Ginsberg MS, Burt ME et al. MRI as an alternative to CT-guided biopsy of adrenal masses in patients with lung cancer. Ann Thorac Surg 1998;65:193-197.
49. Giannone L, Johnson DH, Hande KR et al. Favorable prognosis of brain metastases in small cell lung cancer. Ann Intern Med 1987;106:386-389.
50. Crane JM, Nelson MJ, Ihde DC et al. A comparison of computed tomography and radionuclide scanning for detection of brain metastases in small cell lung cancer. J Clin Oncol 1984;2: 1017-1024.
51. Nugent JL, Bunn PA Jr, Matthews MJ et al. CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival. Cancer 1979;44: 1885-1893.
52. van Oosterhout AG, van de Pol M, ten Velde GP et al. Neurologic disorders in 203 consecutive patients with small cell lung cancer: results of a longitudinal study. Cancer 1996;77:1434-1441.
53. Hardy J, Smith I, Cherryman G et al. The value of computed tomographic (CT) scan surveillance in the detection and management of brain metastases in patients with small cell lung cancer. B rJ Cancer 1990;62:684-686.
54. Hirsch FR, Paulson OB, Hansen HH et al. Intracranial metastases in small cell carcinoma of the lung: correlation of clinical and autopsy findings. Cancer 1982;50:2433-2437.
55. Sculier JP, Feld R, Evans WK et al. Neurologic disorders in patients with small cell lung cancer. Cancer 1987;60:2275-2283.
56. van Hazel GA, Scott M, Eagan RT. The effect of CNS metastases on the survival of patients with small cell cancer of the lung. Cancer 1983;51:933-937.
57. Kochhar R, Frytak S, Shaw EG. Survival of patients with extensive small-cell lung cancer who have only brain metastases at initial diagnosis. Am J Clin Oncol 1997;20:125-127.
58. Johnson DH, Windham WW, Allen JH et al. Limited value of CT brain scans in the staging of small cell lung cancer. AJR Am J Roentgenol 1983;140:37-40.
59. Kristensen CA, Kristjansen PE, Hansen HH. Systemic chemotherapy of brain metastases from small-cell lung cancer: a review. J Clin Oncol 1992;10:1498-1502.
60. Horlyck A, Henriques U, Jakobsen A. The value of bone marrow examination in small cell carcinoma of the lung. Acta Oncol 1994;33:909-911.
61. Campling B, Quirt I, DeBoer G et al. Is bone marrow examination in small-cell lung cancer really necessary? Ann Intern Med 1986; 105:508-512.
62. Bezwoda WR, Lewis D, Livini N. Bone marrow involvement in anaplastic small cell lung cancer: diagnosis, hematologic features, and prognostic implications. Cancer 1986;58:1762-1765.
63. Ihde DC, Simms EB, Matthews MJ et al. Bone marrow metastases in small cell carcinoma of the lung: frequency, description, and influence on chemotherapeutic toxicity and prognosis. Blood 1979;53:677-686.
64. Ihde DC, Makuch RW, Carney DN et al. Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy. Am Rev Respir Dis 1981;123:500-507.
65. Levitan N, Byrne RE, Bromer RH et al. The value of the bone scan and bone marrow biopsy staging small cell lung cancer. Cancer 1985;56:652-654.
66. Trillet V, Revel D, Combaret V et al. Bone marrow metastases in small cell lung cancer: detection with magnetic resonance imaging and monoclonal antibodies. Br J Cancer 1989;60:83-88.
67. Hunter RF, Broadway P, Sun SL et al. Detection of small cell lung cancer bone marrow involvement by discontinuous gradient sedimentation. Cancer Res 1987;47:2737-2740.
68. Pollard EB, Tio F, Myers JW et al. Utilization of a human tumor cloning system to monitor for marrow involvement with small cell carcinoma of the lung. Cancer Res 1981;41:1015-1020.
69. Trillet-Lenoir VN, Arpin D, Brune J. Bone marrow metastases detection in small cell lung cancer: a review. Anticancer Res 1994; 14:2795-2797.
70. Canon JL, Humblet Y, Lebacq-Verheyden AM et al. Immunodetection of small cell lung cancer metastases in bone marrow using three monoclonal antibodies. Eur J Cancer Clin Oncol 1988;24: 147-150.
71. Muss HB, Jackson DV Jr, Richards FD et al. Bone marrow evaluation in small cell lung cancer. Am J Clin Oncol 1984;7:59-63.
72. Hamrick RMD, Murgo AJ. Lactate dehydrogenase values and bone scans as predictors of bone marrow involvement in small-cell lung cancer. Arch Intern Med 1987;147:1070-1071.
73. Milleron BJ, Le Breton C, Carette MF, et al. Assessment of bone marrow involvement by magnetic resonance imaging in small cell lung cancer. No significant change of staging. Chest 1994; 106:1030-1035.
74. Seto T, Imamura F Kuriyama K, et al. Effect on prognosis of bone marrow infiltration detected by magnetic resonance imaging in small cell lung cancer. Eur J Cancer 1997;33:2333-2337.
75. Hochstenbag MMH, Snoep G, Cobben NAM, et al. Detection of bone marrow metastases in small cell lung cancer. Comparison of magnetic resonance imaging with standard methods. Eur J Cancer 1996;32A:779-782.
76. Layer G, Steudel A, Schuller H, et al. Magnetic resonance imaging to detect bone marrow metastases in the initial staging of small cell lung carcinoma and breast carcinoma. Cancer 1999;85: 1004-1009.
77. Jelinek JS, Redmond J, Perry JJ, et al. Small cell lung cancer: staging with MR imaging. Radiology 1990;177:837-842.
78. Levenson RM Jr, Sauerbrunn BJ, Ihde DC et al. Small cell lung cancer: radionuclide bone scans for assessment of tumor extent and response. AJR Am J Roentgenol 1981;137:31-35.
79. Wahl RL, Quint LE, Greenough RL et al. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994;191: 371-377.
80. Kubota K, Matsuzawa T, Fujiwara T et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990;31:1927-1932.
81. Weber W, Young C, Abdel-Dayem HM et al. Assessment of pulmonary lesions with 18F-fluorodeoxyglucose positron imaging using coincidence mode gamma cameras. J Nucl Med 1999;40: 574-578.
82. Kernstine KH, Stanford W, Mullan BF et al. PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma. Ann Thorac Surg 1999;68:1022-1028.
83. Weder W, Schmid RA, Bruchhaus H et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998;66:886-892; discussion 892-893.
84. Vansant JP, Johnson DH, O'Donnell DM et al. Staging lung carcinoma with a Tc-99m labeled monoclonal antibody. Clin Nucl Med 1992;17:431-438.
85. Balaban EP, Walker BS, Cox JV et al. Detection and staging of small cell lung carcinoma with a technetium-labeled monoclonal antibody: a comparison with standard staging methods. Clin Nucl Med 1992;17:439-445.
86. Hochstenbag MM, Heidendal GA, Wouters EF et al. In-111 octreotide imaging in staging of small cell lung cancer. Clin Nucl Med 1997;22:811-816.
87. Berenger N, Moretti JL, Boaziz C et al. Somatostatin receptor imaging in small cell lung cancer. Eur J Cancer 1996;32A: 1429-1431.
88. Reisinger I, Bohuslavitzki KH, Brenner W et al. Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. J Nucl Med 1998;39:224-227.
89. O'Byrne KJ, Ennis JT, Freyne PJ et al. Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue. Br J Cancer 1994;69:762-766.
90. Souhami RL, Bradbury I, Geddes DM et al. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res 1985;45:2878-2882.
91. Fizazi K, Cojean I, Pignon JP et al. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma. Cancer 1998;82:1049-1055.
92. Jorgensen LG, Osterlind K, Genolla J et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres [published erratum appears in Br J Cancer 1996;74: 2043]. Br J Cancer 1996;74:463-467.
93. Harding M, McAllister J, Hulks G et al. Neurone specific enolase (NSE) in small cell lung cancer: a tumour marker of prognostic significance? Br J Cancer 1990;61:605-607.
94. Jorgensen LG, Osterlind K, Hansen HH et al. Serum neuron-specific enolase (S-NSE) in progressive small-cell lung cancer (SCLC). Br J Cancer 1994;70:759-761.
95. Wolf M, Holle R, Hans K et al. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br J Cancer 1991;63:986-992.
96. Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer: a report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research [published erratum appears in Br J Cancer 1990;62:550]. Br J Cancer 1990;61:597-604.
97. Siu LL, Shepherd FA, Murray N et al. Influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Oncol 1996;14:821-828.
98. Morittu L, Earl HM, Souhami RL et al. Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. Br J Cancer 1989;59:801-804.
99. Radford JA, Ryder WD, Dodwell D et al. Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. Eur J Cancer 1992;1:81-86.
100. Stephens RJ, Girling DJ, Machin D. Treatment-related deaths in small cell lung cancer trials: can patients at risk be identified? Medical Research Council Lung Cancer Working Party. Lung Cancer 1994;11:259-274.
101. Lassen UN, Osterling K, Hirsch FR et al. Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression. Br J Cancer 1999;79:515.
102. Bernhard J, Hurny C, Bacchi M et al. Initial prognostic factors in small-cell lung cancer patients predicting quality of life during chemotherapy. Swiss Group for Clinical Cancer Research (SAKK). Br J Cancer 1996;74:1660-1667.
103. Hansen SW, Jensen F, Pedersen NT et al. Detection of liver metastases in small-cell lung cancer: a comparison of peritoneoscopy with liver biopsy and ultrasonography with fine-needle aspiration. J Clin Oncol 1987;5:255-259.
104. Dombernowsky P, Hirsch F, Hansen HH et al. Peritoneoscopy in the staging of 190 patients with small-cell anaplastic carcinoma of the lung with special reference to subtyping. Cancer 1978;41: 2008-2012.
105. Kristjansen PE, Osterlind K, Hansen M. Detection of bone marrow relapse in patients with small cell carcinoma of the lung. Cancer 1986;58:2538-2541.
106. Maeno T, Satoh H, Ishikawa H et al. Patterns of pancreatic metastasis from lung cancer. Anticancer Res 1998;18:2881-2884.
107. Paesmans M, Sculier JP, Bureau G et al. Prognostic factors for response to chemotherapy and for survival among patients with small cell lung cancer: a study by the European lung cancer working party. Proc Am Soc Clin Oncol 1996;15:A1246.
108. Cerny T, Blair V, Anderson H et al. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer 1987;39:146-149.
109. Yuen AR, Zou G, Turrisi AT, et al. Similar outcome of elderly patients in Intergroup Trial 0096. Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer 2000;89:1953-1960.